MX2010008397A - Inhibidores del receptor de quimioquinas cxcr3. - Google Patents
Inhibidores del receptor de quimioquinas cxcr3.Info
- Publication number
- MX2010008397A MX2010008397A MX2010008397A MX2010008397A MX2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A MX 2010008397 A MX2010008397 A MX 2010008397A
- Authority
- MX
- Mexico
- Prior art keywords
- chemokine receptor
- inhibitors
- cxcr3
- receptor cxcr3
- benzsulphonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2973808P | 2008-02-19 | 2008-02-19 | |
| PCT/US2009/034340 WO2009105435A1 (en) | 2008-02-19 | 2009-02-18 | Inhibitors of the chemokine receptor cxcr3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010008397A true MX2010008397A (es) | 2010-08-23 |
Family
ID=40527535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010008397A MX2010008397A (es) | 2008-02-19 | 2009-02-18 | Inhibidores del receptor de quimioquinas cxcr3. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8268828B2 (enExample) |
| EP (1) | EP2262784B1 (enExample) |
| JP (1) | JP2011512412A (enExample) |
| KR (1) | KR20100123835A (enExample) |
| CN (1) | CN102007108A (enExample) |
| AR (1) | AR070430A1 (enExample) |
| AU (1) | AU2009215643A1 (enExample) |
| BR (1) | BRPI0908815A2 (enExample) |
| CA (1) | CA2715557A1 (enExample) |
| CL (1) | CL2009000368A1 (enExample) |
| CO (1) | CO6241113A2 (enExample) |
| CR (1) | CR11604A (enExample) |
| DO (1) | DOP2010000254A (enExample) |
| EC (1) | ECSP10010409A (enExample) |
| IL (1) | IL207597A0 (enExample) |
| MA (1) | MA32191B1 (enExample) |
| MX (1) | MX2010008397A (enExample) |
| NI (1) | NI201000132A (enExample) |
| NZ (1) | NZ587380A (enExample) |
| PE (1) | PE20091576A1 (enExample) |
| RU (1) | RU2010138577A (enExample) |
| SV (1) | SV2010003648A (enExample) |
| TW (1) | TW200948791A (enExample) |
| WO (1) | WO2009105435A1 (enExample) |
| ZA (1) | ZA201005314B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
| JP5807971B2 (ja) | 2009-04-27 | 2015-11-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｘｃｒ３受容体アンタゴニスト |
| US8952004B2 (en) | 2010-01-07 | 2015-02-10 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| KR101251788B1 (ko) | 2010-12-06 | 2013-04-08 | 기아자동차주식회사 | 차량 연비 정보 단말표시 시스템 및 그 방법 |
| JP6162694B2 (ja) | 2011-07-18 | 2017-07-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ベンズアミド類 |
| EP2601950A1 (en) | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
| CN104080784B (zh) * | 2012-01-10 | 2017-07-18 | 默克专利有限公司 | 用作卵泡刺激素调节剂的苯甲酰胺衍生物 |
| EP2809668B1 (en) | 2012-02-02 | 2017-04-12 | Actelion Pharmaceuticals Ltd. | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives |
| EP2666769A1 (en) | 2012-05-23 | 2013-11-27 | Sanofi | Substituted B-amino acid derivatives as CXCR3 receptor antagonist |
| SG11201600504TA (en) | 2013-07-22 | 2016-02-26 | Actelion Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
| AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| US10266526B2 (en) * | 2014-09-10 | 2019-04-23 | Epizyme, Inc. | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| TWI693221B (zh) | 2015-01-15 | 2020-05-11 | 瑞士商愛杜西亞製藥有限公司 | 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物 |
| CA3054945A1 (en) * | 2017-03-26 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6 |
| CN115974766B (zh) * | 2023-01-04 | 2025-05-16 | 中国药科大学 | N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用 |
| CN116410159B (zh) * | 2023-06-09 | 2023-08-22 | 济南国鼎医药科技有限公司 | 一种恩曲替尼中间体的制备方法及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719660A (en) | 1969-06-13 | 1973-03-06 | Takeda Chemical Industries Ltd | 2-furfurylthioinosine-5'-phosphate compounds |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| EP1554253A4 (en) | 2002-06-03 | 2006-09-20 | Smithkline Beecham Corp | IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3 |
| US6734659B1 (en) | 2002-06-13 | 2004-05-11 | Mykrolis Corporation | Electronic interface for use with dual electrode capacitance diaphragm gauges |
| CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
| MX2007009946A (es) * | 2005-02-16 | 2007-09-26 | Schering Corp | Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3. |
| EP1856098B1 (en) | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| US20080312215A1 (en) * | 2005-06-28 | 2008-12-18 | Pharmacopeia Drug Discovery, Inc. | Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders |
| US7781437B2 (en) | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
| US20090143413A1 (en) | 2005-11-29 | 2009-06-04 | Adams Alan D | Thiazole Derivatives as CXCR3 Receptor Modulators |
| AU2007227425A1 (en) | 2006-03-21 | 2007-09-27 | Pharmacopeia, Inc. | Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity |
| US7902199B2 (en) | 2006-07-14 | 2011-03-08 | Schering Corporation | Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity |
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
-
2009
- 2009-02-17 PE PE2009000232A patent/PE20091576A1/es not_active Application Discontinuation
- 2009-02-18 CN CN2009801138321A patent/CN102007108A/zh active Pending
- 2009-02-18 CA CA2715557A patent/CA2715557A1/en not_active Abandoned
- 2009-02-18 EP EP09711984.6A patent/EP2262784B1/en active Active
- 2009-02-18 AU AU2009215643A patent/AU2009215643A1/en not_active Abandoned
- 2009-02-18 JP JP2010547712A patent/JP2011512412A/ja active Pending
- 2009-02-18 AR ARP090100561A patent/AR070430A1/es not_active Application Discontinuation
- 2009-02-18 NZ NZ587380A patent/NZ587380A/en not_active IP Right Cessation
- 2009-02-18 MX MX2010008397A patent/MX2010008397A/es not_active Application Discontinuation
- 2009-02-18 KR KR1020107018467A patent/KR20100123835A/ko not_active Withdrawn
- 2009-02-18 BR BRPI0908815A patent/BRPI0908815A2/pt not_active IP Right Cessation
- 2009-02-18 WO PCT/US2009/034340 patent/WO2009105435A1/en not_active Ceased
- 2009-02-18 RU RU2010138577/04A patent/RU2010138577A/ru not_active Application Discontinuation
- 2009-02-18 CL CL2009000368A patent/CL2009000368A1/es unknown
- 2009-02-19 TW TW098105199A patent/TW200948791A/zh unknown
-
2010
- 2010-07-26 ZA ZA2010/05314A patent/ZA201005314B/en unknown
- 2010-07-28 CR CR11604A patent/CR11604A/es not_active Application Discontinuation
- 2010-07-29 NI NI201000132A patent/NI201000132A/es unknown
- 2010-08-06 US US12/852,076 patent/US8268828B2/en active Active
- 2010-08-12 IL IL207597A patent/IL207597A0/en unknown
- 2010-08-18 EC EC2010010409A patent/ECSP10010409A/es unknown
- 2010-08-18 DO DO2010000254A patent/DOP2010000254A/es unknown
- 2010-08-18 SV SV2010003648A patent/SV2010003648A/es not_active Application Discontinuation
- 2010-08-19 CO CO10102315A patent/CO6241113A2/es not_active Application Discontinuation
- 2010-09-13 MA MA33173A patent/MA32191B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR070430A1 (es) | 2010-04-07 |
| CA2715557A1 (en) | 2009-08-27 |
| CR11604A (es) | 2010-10-05 |
| EP2262784B1 (en) | 2014-04-16 |
| NI201000132A (es) | 2011-03-16 |
| CN102007108A (zh) | 2011-04-06 |
| ZA201005314B (en) | 2011-03-30 |
| NZ587380A (en) | 2011-09-30 |
| EP2262784A1 (en) | 2010-12-22 |
| KR20100123835A (ko) | 2010-11-25 |
| RU2010138577A (ru) | 2012-03-27 |
| CL2009000368A1 (es) | 2009-06-26 |
| ECSP10010409A (es) | 2010-09-30 |
| DOP2010000254A (es) | 2010-08-31 |
| US20100305088A1 (en) | 2010-12-02 |
| WO2009105435A1 (en) | 2009-08-27 |
| JP2011512412A (ja) | 2011-04-21 |
| BRPI0908815A2 (pt) | 2019-09-24 |
| CO6241113A2 (es) | 2011-01-20 |
| PE20091576A1 (es) | 2009-11-05 |
| AU2009215643A1 (en) | 2009-08-27 |
| SV2010003648A (es) | 2011-01-31 |
| MA32191B1 (fr) | 2011-04-01 |
| IL207597A0 (en) | 2010-12-30 |
| TW200948791A (en) | 2009-12-01 |
| US8268828B2 (en) | 2012-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012500674A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
| MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
| DOP2010000254A (es) | Inhibidores del receptor de quimioquinas cxcr3 | |
| TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
| WO2008116920A3 (de) | 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen | |
| ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
| HRP20130797T1 (en) | Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase | |
| WO2009027346A3 (de) | 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen | |
| EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
| MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
| EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| PH12013500274A1 (en) | Heteroaryls and uses thereof | |
| TN2009000012A1 (en) | Amino-piperidine derivatives as cetp inhibitors | |
| ATE551059T1 (de) | Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie | |
| MX2009013353A (es) | Compuestos activadores de telomerasa y metodos para su uso. | |
| TW200602324A (en) | Tetrahydro-indazole cannabinoid modulators cross reference to related applications | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| WO2010042636A3 (en) | Telomerase inhibitors and methods of use thereof | |
| EP2340258A4 (en) | PROCESS FOR THE SYNTHESIS AND APPLICATIONS OF INHIBITORS OF GHRELIN-O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS AGAINST OBESITAS AND DIABETES | |
| ATE517873T1 (de) | 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten | |
| EA201000391A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
| EA201000392A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
| MA32933B1 (fr) | Combinaison d'inhibiteurs de hspo90 et d'herceptine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |